Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.
Summary
The authors identify BMAL1 in alveolar macrophages as a metabolic brake on PFKFB3-driven glycolysis and M1 polarization during SA-ARDS. A biomimetic, inhaled nanoplatform (RM@TNT) delivers a BMAL1 agonist to alveolar macrophages, suppresses glycolysis and inflammation, mitigates lung injury and edema, and improves survival in mice.
Key Findings
- BMAL1 represses PFKFB3 transcription in alveolar macrophages to inhibit glycolysis and M1 polarization.
- An inhalable biomimetic nanoplatform (RM@TNT) targets alveolar macrophages using AM-membrane vesicles and ROS-responsive liposomes.
- RM@TNT delivery of a BMAL1 agonist reduces lung inflammation, injury, and edema and improves survival in SA-ARDS mice.
Clinical Implications
While preclinical, targeting AM glycolysis via BMAL1 activation and inhaled delivery could enable host-directed therapy to dampen lung inflammation in sepsis and complement supportive care for acute respiratory failure.
Why It Matters
This study couples a clearly defined immunometabolic mechanism (BMAL1/PFKFB3) with a precision delivery platform, offering a plausible, organ-targeted therapy for SA-ARDS where options are scarce.
Limitations
- Findings are limited to murine SA-ARDS models; human validation is absent.
- Safety, biodistribution, and scalability of RM@TNT have not been assessed in large animals.
Future Directions
Validate BMAL1/PFKFB3 signatures in human SA-ARDS, assess RM@TNT safety/pharmacology in large animals, and design early-phase trials after dose-finding and manufacturability studies.
Study Information
- Study Type
- Basic/Mechanistic study
- Research Domain
- Pathophysiology/Treatment
- Evidence Level
- V - Preclinical in vivo and in vitro mechanistic evidence; no human subjects
- Study Design
- OTHER